The Role of the Respiratory Microbiome in the Pathogenesis of Aspiration Pneumonia: Implications for Diagnosis and Potential Therapeutic Choices.
Natalia G VallianouAlexandros SkourtisDimitris KounatidisEvangelia MargellouFotis PanagopoulosEleni GeladariAngelos EvangelopoulosEdison JahajPublished in: Antibiotics (Basel, Switzerland) (2023)
Although the lungs were considered to be sterile until recently, the advent of molecular biology techniques, such as polymerase chain reaction, 16 S rRNA sequencing and metagenomics has led to our expanding knowledge of the lung microbiome. These methods may be particularly useful for the identification of the causative agent(s) in cases of aspiration pneumonia, in which there is usually prior administration of antibiotics. The most common empirical treatment of aspiration pneumonia is the administration of broad-spectrum antibiotics; however, this may result in negative cultures from specimens taken from the respiratory tract. Therefore, in such cases, polymerase chain reaction or metagenomic next-generation sequencing may be life-saving. Moreover, these modern molecular methods may assist with antimicrobial stewardship. Based upon factors such as age, altered mental consciousness and recent hospitalization, there is a shift towards the predominance of aerobes, especially Gram-negative bacteria, over anaerobes in aspiration pneumonia. Thus, the therapeutic choices should be expanded to cover multi-drug resistant Gram-negative bacteria in selected cases of aspiration pneumonia.
Keyphrases
- drug resistant
- ultrasound guided
- respiratory tract
- multidrug resistant
- community acquired pneumonia
- respiratory failure
- acinetobacter baumannii
- fine needle aspiration
- gene expression
- cystic fibrosis
- extracorporeal membrane oxygenation
- combination therapy
- genome wide
- mechanical ventilation
- replacement therapy
- smoking cessation